NicOx S.A. | |
Stock Exchange | Other OTC |
EPS |
$0.73 |
Market Cap |
$163.91 M |
Shares Outstanding |
29.59 M |
Public Float |
- |
NicOx S.A. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
29.59 M |
Public Float |
- |
NicOx S.A. | |
Stock Exchange | Euronext Paris |
EPS |
EUR0.62 |
Market Cap |
EUR145.81 M |
Shares Outstanding |
29.91 M |
Public Float |
26.84 M |
Address |
Drakkar 2 - Bât D Sophia-Antipolis Provence-Alpes-Cote-dAzur 06560 France |
Employees | - |
Website | http://www.nicox.com |
Updated | 07/08/2019 |
Nicox SA is an ophthalmology company, which engages in developing innovative solutions to help maintain vision and improve ocular health. Its products include Zerviate, and Vyzulta. The company was founded by Piero Del Soldato, Michele Garufi and Elizabeth Marie Robinson on February 15, 1996 and is headquartered in Sophia-Antipolis, France. |